Splenomegaly

Subscribe to Selected New Research on Splenomegaly

2271 relevant articles (128 outcomes, 91 trials/studies) found for this Disease

Description: Enlargement of the spleen.

Also Known As:

Spleen, Enlarged; Enlarged Spleen

Relationship Network

Disease Context: Research Results

Signs and Symptoms Pathological Conditions

Anatomical Pathological Conditions

Hypertrophy: 13398

Splenomegaly: 2271

Related Diseases

1.	Infection
2.	Lymphatic Diseases (Lymphadenopathy)
3.	Anemia
4.	Hepatomegaly
5.	Primary Myelofibrosis (Myelosclerosis)

Experts

1.	Shen, Ti: 2 articles (01/2008 - 12/2006)
2.	Yang, Ti: 2 articles (01/2008 - 12/2006)
3.	Han, Bing: 2 articles (01/2008 - 12/2006)
4.	Balague, C: 2 articles (12/2007 - 03/2002)
5.	Targarona, E M: 2 articles (12/2007 - 03/2002)
6.	Trias, M: 2 articles (12/2007 - 03/2002)
7.	Papalambros, Efstathios: 2 articles (06/2005 - 12/2004)
8.	Farmakis, Dimitrios: 2 articles (06/2005 - 12/2004)
9.	Deftereos, Spyros: 2 articles (06/2005 - 12/2004)
10.	Tsironi, Maria: 2 articles (06/2005 - 12/2004)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Splenomegaly:

1.	IronIBA 12/02/1960 - "[Clearance of intravenously administered radioactive iron Fe59 from the blood plasma in patients with chronic lymphadenosis and marked splenomegaly.]" 03/01/1989 - "Splenomegaly rates rose appreciably during the study in both groups, but in children at age 2 years the splenomegaly rate at the end of the study was significantly greater in the iron-treated group. " 06/01/2009 - "Strikingly, K(Ca)3.1(-/-)-mice developed progressive splenomegaly which was considerable ( approximately 200% of controls) in the >6-month-old mice and was paralleled by increased iron deposition in the aged mice presumably as a consequence of enhanced RBC sequestration. " 05/01/2008 - "In a low-iron-diet animal model, a significant increase in splenomegaly was observed, but no significant change in bacterial growth was identified. " 05/01/2003 - "The twin sisters presented with an iron deficiency anaemia, associated with an heterozygous sickle-cell anaemia and a moderate splenomegaly. " Order ALL the reference details at left...
2.	Hemoglobins (Hemoglobin)IBA 09/26/1995 - "Heterozygous animals derived from the targeted cells are severely anemic with dramatically reduced hemoglobin levels, abnormal red cell morphology, splenomegaly, and markedly increased reticulocyte counts. " 04/01/2008 - "PB cytogenetic studies resulted in at least two analyzable metaphases in 142 of the 242 study cases (59%); in univariate analysis, this was predicted by the specific clinical diagnosis (P < 0.0001), presence and degree of circulating myeloid progenitor cells or blasts of any lineage (P < 0.0001), higher leukocyte count (P < 0.001), lower platelet count (P = 0.003), lower hemoglobin level (P = 0.002), and presence of palpable splenomegaly (P = 0.002). " 04/01/1992 - "However, there was no correlation between TNF serum levels and other patient characteristics at study enrollment including age, sex, duration of disease, performance status, splenomegaly, WBC count, platelet count, hemoglobin value, prior therapy, and prognostic category. " 05/01/2008 - "Multivariate analysis showed that the clinicohematological variables adversely related to overall survival were serum LDH levels and age, whereas high serum LDH levels, hemoglobin levels of <11 g/dl, and splenomegaly related to treatment-free time (in "wait and see" cases); only splenomegaly related to time to progression (in treated patients). " 10/01/2003 - "Among the two groups, patients with the T-cell LGLL presented with significantly lower hemoglobin concentrations (P < 0.04) and a higher frequency of palpable splenomegaly (P < 0.01). " Order ALL the reference details at left...
3.	Interferon-alpha (Interferon Alfa)FDA Link 03/01/1992 - "The patient obtained a surprising improvement with a significant reduction in the absolute count of the prolymphocytes and considerable reduction in splenomegaly after 3 months' therapy with interferon alpha." 05/01/2004 - "Initially interferon-alpha was administered for a month, decreasing the numbers of leukemic cells but with little effect on splenomegaly. " 05/01/1995 - "Because of high biochemical and histopathological activity with coexisting hepato- and splenomegaly, treatment with alpha interferon was initiated. " 10/01/1988 - "He was treated with alpha-interferon, resulting in disappearance of skin lesions and reduction of his massive splenomegaly from 18 to 5 cm in about 14 months. " 07/01/1995 - "Among the 40 patients who achieved at least a PR, there were 28 with splenomegaly at the beginning of study: the spleen size was reduced in all with interferon alpha therapy and none required splenectomy. " Order ALL the reference details at left...
4.	AutoantibodiesIBA 04/01/2009 - "Treatment with a peptide antagonist of CXCR4 prolonged survival and reduced serum autoantibodies, splenomegaly, intrarenal leukocyte trafficking, and end organ disease in a murine model of lupus. " 11/01/2006 - "In vivo, CLA administration drastically reduced SLE signs (splenomegaly, autoantibodies, and cytokine synthesis), a condition paralleled by the enhancement of GCLC expression and intracellular GSH content. " 12/01/2004 - "At 24 weeks, the treatment group had decreased prevalence of autoantibodies detected by immunofluorescence and less splenomegaly. " 03/17/2003 - "The disease-ameliorating effects were accompanied by reductions in splenomegaly and in several immune cell subsets, including B-1 cells, the major producers of anti-erythrocyte autoantibodies. " 01/01/2003 - "Absence of marked splenomegaly, peripheral blood cytopenias with mild teardrop poikilocytosis and leukoerythroblastosis, bone marrow lymphoid aggregates, and presence of autoantibodies are some of the salient features of primary AIMF. " Order ALL the reference details at left...
5.	Cytarabine (Cytosar-U)FDA LinkGeneric 03/01/1989 - "Small dose of Ara-C relieved her symptoms and splenomegaly. " 01/01/1986 - "Ten patients with myeloproliferative disorders and massive splenomegaly were treated with splenic artery infusions of cytarabine. " 01/01/1986 - "Massive splenomegaly in myeloproliferative disorders treated by splenic artery infusion of cytarabine." 05/01/1979 - "Five patients in the blastic phase of chronic granulocytic leukemia with massive splenomegaly were treated by intraarterial splenic artery infusion of cytosine arabinoside. " 01/20/2005 - "CONCLUSION: In younger adults with normal cytogenetics AML, splenomegaly predicts a lower CR rate, and the postremission strategies of either four cycles of I/HDAC or one cycle of HDAC/etoposide followed by ASCT are associated with improved DFS and reduced relapse compared with therapies that include fewer cycles of cytarabine or no transplantation." Order ALL the reference details at left...
6.	Pentostatin (Nipent)FDA LinkGeneric 11/01/1992 - "After administration of deoxycoformycin (DCF) at a dose of 5.0mg/m2 1-2 times monthly, splenomegaly disappeared, as did hairy cells from the peripheral blood. " 05/01/2001 - "[European-American-type hairy cell leukemia without splenomegaly, treated successfully with deoxycoformycin]" 12/01/1984 - "A woman with hairy-cell leukemia has begun treatment with pentostatin, and at ten weeks there is disappearance of gross splenomegaly and clearance of hairy cells from the blood. " 04/01/1995 - "A multivariate logistic regression analysis of the confirmed complete remissions on pentostatin showed the following factors to be important for achieving a complete remission: high hemoglobin level (two-tailed P = .024), young age (P = .0085), and no or little splenomegaly (P = .0029). " Order ALL the reference details at left...
7.	AntigensIBA 12/01/1989 - "In the Upper Watut Valley of Papua New Guinea, where over 80% of adult inhabitants are known to develop the disease, human leucocyte antigen (HLA) studies have demonstrated an association between the antigen DR2 and gross splenomegaly. " 10/01/2002 - "However, animals developed splenomegaly as a result of accumulated memory T cells that were not deleted after antigen-driven expansion. " 07/01/1997 - "Hyperreactive malarious splenomegaly: immunohistochemical demonstration of Plasmodium falciparum antigen in liver cells." 01/01/1990 - "The recursive partitioning analysis defined three groups of patients with widely varied prognoses identified as follows: (1) those with a WBC count less than 50 x 10(3)/microL who lacked massive splenomegaly and had blasts expressing CD5 had the best prognosis (66%, SE = 7%, EFS 4 years, n = 84); (2) those with (b1) WBC counts less than 50 x 10(3)/microL with either massive splenomegaly or who had blasts lacking CD5 expression, or (b2) WBC counts greater than 50 x 10(3)/microL with expression of the THY antigen had an intermediate prognosis (39%, SE = 7% EFS at 4 years, n = 94); (3) those with WBC counts greater than 50 x 10(3)/microL and whose blasts lacked expression of THY antigen had the poorest outcome (EFS = 19% at 4 years, SE = 8%, n = 63). " 10/01/1987 - "Splenocytes from thymus-implanted animals failed to achieve GVH-induced splenomegaly when transferred to appropriate hosts (bearing MHC antigens of the thymus donor strain). " Order ALL the reference details at left...
8.	Immunoglobulin G (IgG)IBA 01/01/2009 - "A positive correlation between elevated levels of anti-malarial IgG and IgG3 and splenomegaly was noted only within the Fulani group. " 07/01/2006 - "CVID patients with splenomegaly, lower pre-infusion IgG levels (< 600 mg/dl), autoimmune or lymphoproliferative conditions demonstrated even higher levels of CD4+CD38+DR+T cells (22, 22, 21 and 21% respectively) compared with other CVID patients (13, 13, 15 and 15% respectively). " 09/01/2001 - "The 4-1BBL-transgenic mice show progressive splenomegaly and selective depletion of B220(+) B cells accompanied with low levels of circulating IgG and defective humoral responses to Ag challenge. " 01/01/1997 - "Results indicated that Se treatment 0.1 mg/kg/d (p.o.) inhibited splenomegaly and sera IgG elevation effectively. " 08/01/1996 - "At the maternal level, this treatment causes splenomegaly, decrease of hematocrit levels, and increase of IgG production. " Order ALL the reference details at left...
9.	DNA (Deoxyribonucleic Acid)IBA 10/01/2008 - "Here, we report that aged DC-STAMP-deficient mice display several systemic autoimmune symptoms such as spontaneous lymphoproliferation, splenomegaly associated with infiltration of T cells in several organs and increased serum anti-double-stranded DNA antibody production. " 03/01/2008 - "One tested negative for both EBV DNA and splenomegaly. " 03/01/2008 - "Six rabbits demonstrated transient splenomegaly, increased anti-EBV-VCA titers and/or EBV-DNA in blood. " 04/01/1986 - "B6 Lyt-2+ cells responded strongly to the class I different mutant, bm1, as manifested by DNA synthesis in the spleen of irradiated mice followed by entry of blast cells into thoracic duct lymph, induction of splenomegaly in newborn mice, production of lethal GVHD in irradiated mice, and skin allograft rejection. " 12/01/2008 - "By contrast, transient exposure to non-CpG DNA exacerbate lupus nephritis in association with splenomegaly, lymphoproliferation, hypergammaglobulinaemia and increased B220(+)CD138(+) plasma cells. " Order ALL the reference details at left...
10.	Hydroxyurea (Hydrea)FDA LinkGeneric 12/01/2005 - "For elderly patients, oral hydroxyurea is suitable for the relief of symptoms caused by hyperleukocytosis, and splenic irradiation would be considered if abdominal discomfort or fullness induced by splenomegaly were present. " 12/01/1993 - "The administration of hydroxyurea and low dose splenic irradiation were initiated for abdominal distention due to splenomegaly in 1987. " 07/01/1991 - "Both patients presented with rapidly increasing splenomegaly which was resistant to treatment with hydroxyurea and external beam irradiation. " 01/01/2001 - "All responded initially to therapy with hydroxyurea with control of leukocytosis and reduction in splenomegaly. " 10/01/1989 - "Orally administered hydroxyurea controlled leukocytosis and splenomegaly in some patients without affecting the overall prognosis." Order ALL the reference details at left...

Therapies and Procedures

1.	Splenectomy 05/01/2002 - "Laparoscopic splenectomy was safe and effective in patients with benign disease, even in cases of marked splenomegaly. " 11/01/2006 - "CONCLUSIONS: With good perioperative management, splenectomy in children with SCA is not only safe, but also beneficial in treating SA, reducing the patients' transfusion requirements, eliminating the risks of ASSC, and eliminating the discomfort and mechanical pressure of the enlarged spleen. " 07/01/1999 - "CONCLUSIONS: With good perioperative management, splenectomy in children with massive splenomegaly is both safe and effective." 05/01/1992 - "It is concluded that splenectomy is beneficial in advanced cases of CLL with massive splenomegaly and cytopenia." 03/01/2003 - "Splenectomy was the first effective treatment because it resulted in an improvement in cytopenias and relief from symptomatic splenomegaly. " Order ALL the reference details at left...
2.	Drug Therapy (Chemotherapy) 07/01/2005 - "An abdominal ultrasonogram revealed a huge splenomegaly with multiple ill-defined low echogenic nodules, 1 month after the second cycle of chemotherapy. " 02/01/2002 - "Splenomegaly recurred after cessation of the chemotherapy, and examination of the peripheral blood showed 31% blasts, positive for both CD13 and CD33, on which basis myeloid blastic transformation was diagnosed. " 11/01/1998 - "Splenic irradiation was added because of persistent splenomegaly in spite of intensive chemotherapy. " 09/01/1997 - "Six patients with splenomegaly and/or requirement for chemotherapy had significantly higher mean blood levels of CD34+ cells compared to the remaining PV patients. " 03/01/1995 - "The response obtained was independent of the pretreatment serum EPO levels, the duration of anaemia, the concomitant administration of chemotherapy, the presence of splenomegaly, or the degree of bone marrow infiltration by lymphocytes. " Order ALL the reference details at left...
3.	Aftercare (After-Treatment) 09/01/2007 - "After treatment, all patients had a complete resolution of splenomegaly along with restoration of their blood counts. " 01/01/2006 - "Four years after treatment, 42 of the 84 individuals were re-examined and regression of splenomegaly was observed in 59% and of periportal thickening in 32%. " 05/01/2001 - "Two months after treatment ended, the 7-year-old girl developed splenomegaly, cervical adenopathy, and bilateral interstitial pulmonary infiltrates. " 07/01/1999 - "BCG treated rats showed hepatic and splenomegaly, both 48 and 6 days after treatment. " 01/01/1994 - "In addition, the splenic index was calculated before and after treatment to detect residual splenomegaly. " Order ALL the reference details at left...
4.	Transplants (Transplant) 02/01/1975 - "Lymphoid cells from mice with long surviving skin grafts were found to be reactive in graft-versus-host assays (as measured by splenomegaly or popliteal lymph node enlargement), and mixed lymphocyte culture tests gave positive results. " 02/01/1989 - "A study on graft-versus-host reaction (GVHR) by Simonsen's splenomegaly assay. " 12/01/2008 - "However, because of the impossibility of mobilization of the lateral section due to severe splenomegaly at the time of the recipient operation, we performed an APOLT using a right lobe graft. " 03/01/2002 - "This is characterized by an arterial malperfusion of the hepatic graft caused by a marked diversion of blood flow to a significantly enlarged spleen, which leads to major ischemic damage of the hepatic graft. " 01/01/1993 - "The turkey major histocompatibility complex: characterization by mixed lymphocyte, graft-versus-host splenomegaly, and skin graft reactions." Order ALL the reference details at left...
5.	Blood Transfusion (Blood Transfusions) 11/01/1998 - "RESULTS: Patients in group 1 required longer operative time and significantly less intraoperative blood transfusion compared with group 2. The postoperative course was less complicated and shorter in group 1 than in group 2. Operative time was longer in group 1 compared with group 3. No significant differences in terms of postoperative course have been found between groups 1 and 3. CONCLUSIONS: Laparoscopy for splenomegaly is a feasible, effective, and safe technique for experienced laparoscopic surgeons. " 02/01/2001 - "The remaining patient suffered from moderate to severe chronic non-spherocytic haemolytic anaemia and splenomegaly, and required occasional blood transfusion for a haemolytic crisis associated with drug ingestion. " 04/01/1998 - "Splenomegaly, observed in 59 cases (69.4%), does not statistically correlate with life style and blood transfusions. " 02/01/1996 - "During infancy all three patients had unusually severe clinical manifestations for HbH disease, with anaemia necessitating blood transfusions, signs of bone changes, growth impairment, and splenomegaly. " 10/01/1991 - "It was characterized by a moderate anaemia, microcytosis and hypochromia, anisopoikilocytosis, Heinz body formation in peripheral red cells, splenomegaly, and a blood transfusion requirement during pregnancy. " Order ALL the reference details at left...

Best Treatments:
Research Summary Report
on Splenomegaly

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 128 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>